BioCatalystWatch
RIGLWorkspace / RIGL / OverviewCompany library
RIGEL PHARMACEUTICALS INC logo

RIGEL PHARMACEUTICALS INC

RIGEL PHARMACEUTICALS INC (RIGL)

Website

Price
Market cap
Next catalystDec 8-11, 2026VEPPANU (vepdegestrant) · Phase 3 dataCompany presentation ↗
Cash

Chart & Events

Candle interval

Core Clinical

R289

IRAK1 × IRAK4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

R289

IRAK1 × IRAK4

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

fostamatinib (TAVALISSE)

SYK

PreINDP1P2P3FilingApproved
AZ-D0449

JAK

PreINDP1P2P3FilingApproved
R5526

RIP kinase

PreINDP1P2P3FilingApproved
R8357

IRAK

PreINDP1P2P3FilingApproved
R112

SYK

PreINDP1P2P3FilingApproved

Partner / License out

AXL

PreINDP1P2P3FilingApproved

AXL

PreINDP1P2P3FilingApproved

AXL

PreINDP1P2P3FilingApproved

Approved / commercial

olutasidenib (REZLIDHIA)

mIDH1

PreINDP1P2P3FilingApproved
fostamatinib (TAVALISSE)

SYK

PreINDP1P2P3FilingApproved

History / paused

JAK1 × JAK3

PreINDP1P2P3FilingApproved

JAK1 × JAK3

PreINDP1P2P3FilingApproved

MDM2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

RIGL PR & News

PR & News

RIGL SEC archive